Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03502577
Recruitment Status : Suspended (Waiting on confirmation of additional funding)
First Posted : April 18, 2018
Last Update Posted : February 4, 2022
Juno Therapeutics, Inc.
The Leukemia and Lymphoma Society
Information provided by (Responsible Party):
Fred Hutchinson Cancer Center

No Study Results Posted on for this Study
Recruitment Status : Suspended
Estimated Primary Completion Date : April 14, 2022
Estimated Study Completion Date : April 14, 2022